Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Expert Review of Anticancer Therapy|March 1, 2014
Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancerEva Ciruelos, Christian Jackisch
Breast Care (Basel, Switzerland)|October 16, 2018
Standard Neoadjuvant Treatment in Early/Locally Advanced Breast CancerCristina Pernaut, Flora Lopez, Eva Ciruelos
Med (New York, N.Y.)|September 13, 2025
Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancerPablo Tolosa, Juan Montes, Eva Ciruelos
Med (New York, N.Y.)|February 15, 2025
Oral SERDs: Transforming the treatment of advanced breast cancer-Insights from EMBER-3Manuel Alva-Bianchi, Rodrigo Sánchez-Bayona, Eva Ciruelos
Anti-Cancer Drugs|July 11, 2013
Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancerEva Ciruelos, Hernán Cortes-Funes, Ismael Ghanem, et al.
Breast Care (Basel, Switzerland)|August 11, 2020
Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA FeaturesMercedes Herrera Juarez, Pablo Tolosa Ortega, Ana Sanchez de Torre, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 29, 2012
Behaviour of breast cancer molecular subtypes through tumour progressionCarlos A Castaneda, Eva Andrés, Carmen Barcena, et al.
Clinical Drug Investigation|May 5, 2019
Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old ConceptEva Ciruelos, José Manuel Pérez-García, Joaquín Gavilá, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed in bladder, head and neck, and cervical cancersLuis Paz-Ares, Eva Ciruelos, Rocío García-Carbonero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 9, 2024
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event managementEva Ciruelos, Jose Ángel García-Sáenz, Joaquín Gavilá, et al.
Pageof 13